Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2014 2
2015 1
2018 1
2019 3
2021 4
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Membranous Nephropathy - Autoimmune Disorder Associated"
Page 1
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders.
Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, Crowley C, Boyman O. Kaegi C, et al. Front Immunol. 2019 Sep 6;10:1990. doi: 10.3389/fimmu.2019.01990. eCollection 2019. Front Immunol. 2019. PMID: 31555262 Free PMC article.
Conversely, rituximab failed to show an effect for antiphospholipid syndrome, autoimmune hepatitis, IgA nephropathy, inflammatory myositis, primary-progressive multiple sclerosis, systemic lupus erythematosus, and ulcerative colitis. Finally, mixed results were repo …
Conversely, rituximab failed to show an effect for antiphospholipid syndrome, autoimmune hepatitis, IgA nephropathy, inflammat …
Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
Kaegi C, Wuest B, Crowley C, Boyman O. Kaegi C, et al. Front Immunol. 2022 Feb 2;12:788830. doi: 10.3389/fimmu.2021.788830. eCollection 2021. Front Immunol. 2022. PMID: 35185862 Free PMC article.
CONCLUSIONS: Obinutuzumab has shown promising results in a case series of patients with phospholipase A(2) receptor-associated membranous nephropathy and mixed results in systemic lupus erythematosus. ...Moreover, ofatumumab showed promising results in patien …
CONCLUSIONS: Obinutuzumab has shown promising results in a case series of patients with phospholipase A(2) receptor-associated mem …
Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
von Groote TC, Williams G, Au EH, Chen Y, Mathew AT, Hodson EM, Tunnicliffe DJ. von Groote TC, et al. Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD004293. doi: 10.1002/14651858.CD004293.pub4. Cochrane Database Syst Rev. 2021. PMID: 34778952 Free PMC article. Review.
BACKGROUND: Primary membranous nephropathy (PMN) is a common cause of nephrotic syndrome in adults. ...An alkylating agent (cyclophosphamide or chlorambucil) combined with a corticosteroid regimen had short- and long-term benefits, but this was associated wit …
BACKGROUND: Primary membranous nephropathy (PMN) is a common cause of nephrotic syndrome in adults. ...An alkylating agent (cy …
Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies.
Leeaphorn N, Kue-A-Pai P, Thamcharoen N, Ungprasert P, Stokes MB, Knight EL. Leeaphorn N, et al. Am J Nephrol. 2014;40(1):29-35. doi: 10.1159/000364782. Epub 2014 Jun 28. Am J Nephrol. 2014. PMID: 24993974 Free article. Review.
BACKGROUND: The association between membranous nephropathy (MN) and cancer has been well documented. ...CONCLUSION: The estimated prevalence of cancer in patients with MN is 10% (95% CI, 6.1-14.6). The vast majority of tumors associated with MN are lun …
BACKGROUND: The association between membranous nephropathy (MN) and cancer has been well documented. ...CONCLUSION: The …
Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis.
Tang KT, Tseng CH, Hsieh TY, Chen DY. Tang KT, et al. Int J Rheum Dis. 2018 Jun;21(6):1163-1172. doi: 10.1111/1756-185X.13321. Int J Rheum Dis. 2018. PMID: 29879319 Review.
AIM: Membranous lupus glomerulonephritis (MLN) is associated with morbidities such as thromboembolism, peripheral edema and/or hyperlipidemia. ...NMA results showed that both mycophenolate mofetil (MMF) and calcineurin inhibitors (CNI) are effective in the in …
AIM: Membranous lupus glomerulonephritis (MLN) is associated with morbidities such as thromboembolism, peripheral edema …
Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe Proteinuria: A Systematic Review and Network Meta-Analysis.
Chen M, Liu J, Xiong Y, Xu G. Chen M, et al. Int J Clin Pract. 2022 Apr 23;2022:4996239. doi: 10.1155/2022/4996239. eCollection 2022. Int J Clin Pract. 2022. PMID: 35685506 Free PMC article. Review.
OBJECTIVE: Numerous studies have demonstrated that the efficacy of drugs differs in idiopathic membranous nephropathy (IMN) patients with moderate or high proteinuria. ...Rituximab (RTX) was more beneficial for TR on patients with proteinuria <8 g/d (SUCRA 66.0%) …
OBJECTIVE: Numerous studies have demonstrated that the efficacy of drugs differs in idiopathic membranous nephropathy (IMN) pa …
Efficacy of low or heavy rituximab-based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.
Chen M, Zhang X, Xiong Y, Xu G. Chen M, et al. Int Urol Nephrol. 2023 Mar;55(3):641-651. doi: 10.1007/s11255-022-03372-5. Epub 2022 Sep 25. Int Urol Nephrol. 2023. PMID: 36161550 Review.
OBJECTIVE: Numerous studies have demonstrated the efficiency of tacrolimus + rituximab and rituximab in idiopathic membranous nephropathy (IMN). But optimal dosages of rituximab for IMN are still controversial. ...Tacrolimus and cyclosporine A were associated …
OBJECTIVE: Numerous studies have demonstrated the efficiency of tacrolimus + rituximab and rituximab in idiopathic membranous neph …
Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels.
Xue C, Wang J, Pan J, Liang C, Zhou C, Wu J, Song S, Cui L, Zhang L, Liu Y, Dai B. Xue C, et al. BMC Nephrol. 2023 Sep 22;24(1):280. doi: 10.1186/s12882-023-03307-x. BMC Nephrol. 2023. PMID: 37740193 Free PMC article.
Rituximab (RTX) and cyclophosphamide (CYC) based treatments are both recommended as first-line therapies in idiopathic membranous nephropathy (IMN) by KDIGO 2021 guideline. However, the efficacy of RTX vs. ...RTX induced a similar overall remission rate compared wit …
Rituximab (RTX) and cyclophosphamide (CYC) based treatments are both recommended as first-line therapies in idiopathic membranous …
The Influence and Role of Microbial Factors in Autoimmune Kidney Diseases: A Systematic Review.
Kronbichler A, Kerschbaum J, Mayer G. Kronbichler A, et al. J Immunol Res. 2015;2015:858027. doi: 10.1155/2015/858027. Epub 2015 May 18. J Immunol Res. 2015. PMID: 26078982 Free PMC article. Review.
A better understanding of the pathophysiology of autoimmune disorders is desired to allow tailored interventions. Despite increased scientific interest a direct pathogenic factor in autoimmune renal disease has been described only in a minority like membranous …
A better understanding of the pathophysiology of autoimmune disorders is desired to allow tailored interventions. Despite increased s …
Clinical characteristics of membranous nephropathy with spontaneous remission: An analysis of 24 patients.
Wang X, Zhang J, Zou GM, Zheng XM, Li JY, Gao HM, Jiang SM, Li WG. Wang X, et al. Med Clin (Barc). 2023 May 26;160(10):421-427. doi: 10.1016/j.medcli.2022.10.014. Epub 2023 Jan 21. Med Clin (Barc). 2023. PMID: 36690554 Free article. English, Spanish.
PURPOSE: To investigate the prognosis of patients with spontaneous remission (SR) of phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN). PATIENTS AND METHODS: Patients diagnosed with MN were recruited after examining their renal biopsy i …
PURPOSE: To investigate the prognosis of patients with spontaneous remission (SR) of phospholipase A2 receptor (PLA2R)-associated …
17 results